The effects of mirtazapine on sleep in patients with major depressive disorder

Annals of Clinical Psychiatry

Volumn 24, Issue 3, 2012, Pages 215-224

  Dolder, Christian R ^a,b   Nelson, Michael H ^c   Iler, Cameron A ^a  

^a WINGATE UNIVERSITY   (United States)

^b Carolinas Medical Center NorthEast   (United States)

^c REGIS UNIVERSITY   (United States)

Author keywords

Major depressive disorder; Mirtazapine; Sleep

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; FLUOXETINE; MIRTAZAPINE; PAROXETINE; PLACEBO; VENLAFAXINE;

DROWSINESS; DRUG DOSE TITRATION; FATIGUE; HUMAN; INFORMATION RETRIEVAL; LOW DRUG DOSE; MAJOR DEPRESSION; MENTAL PATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SIDE EFFECT; SLEEP; SLEEP QUALITY; SLEEP TIME;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER, MAJOR; HUMANS; MIANSERIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP;

EID: 84865227304     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. American Psychiatric Association. Treatment of patients with major depressive disorder. 3rd ed. http://psychiatryonline.org/content.aspx?bookid= 28§ionid=1667485. Accessed May 10, 2012.
2. Suehs BT, Argo TR, Bendele SD, et al. Texas Medication Algorithm Project procedural manual: major depressive disorder algorithms. Austin, TX: The Texas Department of State Health Services; 2008.
3. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7:249-264. (Pubitemid 34016084)
4. Horwath E, Johnson J, Weissman MM, et al. The validity of major depression with atypical features based on a community study. J Affect Disord. 1992;26:117-125.
5. Jindal RD. Insomnia in patients with depression: some pathophysiological and treatment considerations. CNS Drugs. 2009;23:309-329.
6. Nutt DJ. Tolerability and safety aspects of mirtazapine. Hum Psychopharmacol. 2002;17(suppl 1):S37-S41. (Pubitemid 34678890)
7. Parker G, Malhi G, Hadzi-Pavlovic D, et al. Sleeping in? The impact of age and depressive sub-type on hypersomnia. J Affect Disord. 2006;90:73-76. (Pubitemid 43005041)
8. Parker G, Roy K, Mitchell P, et al. Atypical depression: a reappraisal. Am J Psychiatry. 2002;159:1470-1479. (Pubitemid 35006725)
9. Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry. 1999;60(suppl 17):28-31;discussion 46-48.
10. Papakostas GI. Limitations of contemporary antidepressants: tolerability. J Clin Psychiatry. 2007;68(suppl 10):11-17. (Pubitemid 47507832)
11. Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs. 2009;23:427-452.
12. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol. 2005;20:533-559. (Pubitemid 43056116)
13. Monti JM. Serotonin control of sleep-wake behavior. Sleep Med Rev. 2011;15:269-281.
14. Sharpley AL, Elliott JM, Attenburrow MJ, et al. Slow wave sleep in humans: role of 5-HT2A and 5-HT2C receptors. Neuropharmacology. 1994;33:467-471.
15. Hicks JA, Argyropoulos SV, Rich AS, et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiatry. 2002;180:528-535. (Pubitemid 34596804)
16. Sharpley AL, Vassallo CM, Cowen PJ. Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT(2C) receptors in vivo. Biol Psychiatry. 2000;47:468-470. (Pubitemid 30110618)
17. Kang RH, Choi MJ, Paik JW, et al. Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression. Int J Psychiatry Med. 2007;37:315-329.
18. Holm KJ, Markham A. Mirtazapine: a review of its use in major depression. Drugs. 1999;57:607-631. (Pubitemid 29196924)
19. Winokur A, Sateia MJ, Hayes JB, et al. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol Psychiatry. 2000;48:75-78. (Pubitemid 30407153)
20. Freynhagen R, Muth-Selbach U, Lipfert P, et al. The effect of mirtazapine in patients with chronic pain and concomitant depression. Curr Med Res Opin. 2006;22:257-264. (Pubitemid 44296749)
21. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol. 1995;10(suppl 4):37-45. (Pubitemid 26058318)
22. Grasmäder K, Verwohlt PL, Kuhn KU, et al. Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. Pharmacopsychiatry. 2005;38:113-117.
23. Davis R, Wilde MI. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs. 1996;5:389-402.
24. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996;57(suppl 4):19-25.
25. Radhakishun FS, van den Bos J, van der Heijden BC, et al. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychopharmacol. 2000;20:531-537.
26. Agargun MY, Kara H, Solmaz M. Sleep disturbances and suicidal behavior in patients with major depression. J Clin Psychiatry. 1997;58:249-251. (Pubitemid 27318559)
27. Buysse DJ, Tu XM, Cherry CR, et al. Pretreatment REM sleep and subjective sleep quality distinguish depressed psychotherapy remitters and nonremitters. Biol Psychiatry. 1999;45:205-213. (Pubitemid 29079451)
28. Cho HJ, Lavretsky H, Olmstead R, et al. Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study. Am J Psychiatry. 2008;165:1543-1550.
29. Dew MA, Reynolds CF 3rd, Houck PR, et al. Temporal profiles of the course of depression during treatment. Predictors of pathways toward recovery in the elderly. Arch Gen Psychiatry. 1997;54:1016-1024. (Pubitemid 27476097)
30. Fawcett J, Scheftner WA, Fogg L, et al. Time-related predictors of suicide in major affective disorder. Am J Psychiatry. 1990;147:1189-1194. (Pubitemid 20275373)
31. Goldstein TR, Bridge JA, Brent DA. Sleep disturbance preceding completed suicide in adolescents. J Consult Clin Psychol. 2008;76:84-91. (Pubitemid 351215332)
32. Thase ME, Simons AD, Reynolds CF 3rd. Abnormal electroencephalographic sleep profiles in major depression: association with response to cognitive behavior therapy. Arch Gen Psychiatry. 1996;53:99-108. (Pubitemid 26049386)
33. Benca RM, Obermeyer WH, Thisted RA, et al. Sleep and psychiatric disorders. A meta-analysis. Arch Gen Psychiatry. 1992;49:651-668; discussion 669-670.
34. Stickgold R, Hobson JA, Fosse R, et al. Sleep, learning, and dreams: off-line memory reprocessing. Science. 2001;294:1052-1057. (Pubitemid 33041854)
35. Armitage R. Microarchitectural findings in sleep EEG in depression: diagnostic implications. Biol Psychiatry. 1995;37:72-84.
36. Farina B, Della Marca G, Grochocinski VJ, et al. Microstructure of sleep in depressed patients according to the cyclic alternating pattern. J Affect Disord. 2003;77:227-235. (Pubitemid 37377916)
37. Jindal RD, Friedman ES, Berman SR, et al. Effects of sertraline on sleep architecture in patients with depression. J Clin Psychopharmacol. 2003;23:540-548. (Pubitemid 37443184)
38. Jindal RD, Thase ME, Fasiczka AL, et al. Electroencephalographic sleep profiles in single-episode and recurrent unipolar forms of major depression: II. Comparison during remission. Biol Psychiatry. 2002;51:230-236. (Pubitemid 34142635)
39. Terzano MG, Parrino L, Sherieri A, et al. Atlas, rules, and recording techniques for the scoring of cyclic alternating pattern (CAP) in human sleep. Sleep Med. 2001;2:537-553. (Pubitemid 34026954)
40. Cankurtaran ES, Ozalp E, Soygur H, et al. Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer. 2008;16:1291-1298.
41. Claghorn JL, Lesem MD. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord. 1995;34:165-171.
42. Schatzberg AF, Kremer C, Rodrigues HE, et al; Mirtazapine vs. Paroxetine Study Group. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry. 2002;10:541-550. (Pubitemid 34984390)
43. Wheatley DP, van Moffaert M, Timmerman L, et al. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J Clin Psychiatry. 1998;59:306-312. (Pubitemid 28353979)
44. Benkert O, Szegedi A, Philipp M, et al. Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. J Clin Psychopharmacol. 2006;26:75-78. (Pubitemid 43167095)
45. Bruijn JA, Moleman P, Mulder PG, et al. Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry. 1999;32:87-92. (Pubitemid 29364441)
46. Danileviciute V, Sveikata A, Adomaitiene V, et al. Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania. Medicina (Kaunas). 2009;45:778-784.
47. Guelfi JD, Ansseau M, Timmerman L, et al. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol. 2001;21:425-431. (Pubitemid 32673032)
48. Hoyberg OJ, Maragakis B, Mullin J, et al. A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand. 1996;93:184-190. (Pubitemid 26142849)
49. Roose SP, Nelson JC, Salzman C, et al. Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home. Curr Med Res Opin. 2003;19:737-746. (Pubitemid 37466144)
50. Schmid DA, Wichniak A, Uhr M, et al. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology. 2006;31:832-844.
51. Versiani M, Moreno R, Ramakers-van Moorsel CJ, et al Comparative Efficacy Antidepressants Study Group. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs. 2005;19:137-146. (Pubitemid 40321765)
52. Winokur A, DeMartinis NA 3rd, McNally DP, et al. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry. 2003;64:1224-1229.
53. Zivkov M, de Jongh GD. Org 3770 versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients. Hum Psychopharmacol. 1995;10:173-180.
54. Kim SW, Shin IS, Kim JM, et al. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci. 2008;62:75-83.
55. Schittecatte M, Dumont F, Machowski R, et al. Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology. 2002;46:197-201. (Pubitemid 36173369)
56. Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol. 1999;14:329-337. (Pubitemid 29531381)
57. Shen J, Chung SA, Kayumov L, et al. Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Can J Psychiatry. 2006;51:27-34. (Pubitemid 43234943)
58. Schittecatte M, Dumont F, Machowski R, et al. Mirtazapine, but not fluvoxamine, normalizes the blunted REM sleep response to clonidine in depressed patients: implications for subsensitivity of alpha(2)-adrenergic receptors in depression. Psychiatry Res. 2002;109:1-8. (Pubitemid 34159304)
59. Geyer JD, Carney PR, Dillard SC, et al. Antidepressant medications, neuroleptics, and prominent eye movements during NREM sleep. J Clin Neurophysiol. 2009;26:39-44.
60. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord. 1998;51:267-285. (Pubitemid 29202175)
61. Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol. 2008;22:843-848.
62. Kasper S, Zivkov M, Roes KC, et al. Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. Eur Neuropsychopharmacol. 1997;7:115-124. (Pubitemid 27240345)
63. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry. 2000;61:656-663.
64. Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs? J Clin Psychiatry. 2001;62:358-361. (Pubitemid 32545558)
65. Wade A, Crawford GM, Angus M, et al. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Int Clin Psychopharmacol. 2003;18:133-141. (Pubitemid 36571056)
66. Watanabe N, Omori IM, Nakagawa A, et al. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. J Clin Psychiatry. 2008;69:1404-1415.
67. Walinder J, Prochazka J, Oden A, et al. Mirtazapine naturalistic depression study (in Sweden)-MINDS(S): clinical efficacy and safety. Hum Psychopharmacol. 2006;21:151-158. (Pubitemid 43670664)
68. Watanabe N, Omori IM, Nakagawa A, et al. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs. 2010;24:35-53.
69. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry. 1995;56:519-525.
70. Smith WT, Glaudin V, Panagides J, et al. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull. 1990;26:191-196. (Pubitemid 20291874)
71. Ridout F, Meadows R, Johnsen S, et al. A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance. Hum Psychopharmacol. 2003;18:261-269. (Pubitemid 36722311)
72. Wingen M, Bothmer J, Langer S, et al. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry. 2005;66:436-443. (Pubitemid 40593571)
73. Brunnauer A, Laux G, Geiger E, et al. Antidepressants and driving ability: results from a clinical study. J Clin Psychiatry. 2006;67:1776-1781. (Pubitemid 44955160)